CWM LLC boosted its holdings in Becton Dickinson and Co (NYSE:BDX) by 34.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,120 shares of the medical instruments supplier’s stock after purchasing an additional 290 shares during the quarter. CWM LLC’s holdings in Becton Dickinson and were worth $280,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. IMS Capital Management purchased a new position in shares of Becton Dickinson and during the third quarter valued at $29,000. RPG Investment Advisory LLC bought a new stake in Becton Dickinson and during the first quarter valued at about $32,000. Nalls Sherbakoff Group LLC bought a new stake in Becton Dickinson and during the fourth quarter valued at about $34,000. Aspire Private Capital LLC bought a new stake in Becton Dickinson and during the fourth quarter valued at about $39,000. Finally, Sontag Advisory LLC bought a new stake in Becton Dickinson and during the fourth quarter valued at about $43,000. Institutional investors and hedge funds own 85.24% of the company’s stock.
A number of equities research analysts recently weighed in on the company. Barclays raised their price objective on Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research report on Monday, April 15th. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, April 22nd. Wells Fargo & Co lowered their price target on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a report on Monday, May 13th. TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. Finally, Morgan Stanley lowered their price target on Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating for the company in a report on Friday, May 10th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $255.31.
In other news, CEO Vincent A. Forlenza sold 3,123 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the sale, the chief executive officer now directly owns 215,372 shares in the company, valued at $54,926,321.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vincent A. Forlenza sold 11,340 shares of the business’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the sale, the chief executive officer now owns 227,250 shares of the company’s stock, valued at $56,903,400. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,384 shares of company stock valued at $7,901,023. 0.12% of the stock is owned by company insiders.
BDX stock traded up $1.71 during trading on Wednesday, hitting $235.68. 1,223,285 shares of the company traded hands, compared to its average volume of 1,276,401. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. The stock has a market cap of $61.60 billion, a P/E ratio of 21.41, a P/E/G ratio of 1.71 and a beta of 1.16. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. Becton Dickinson and’s quarterly revenue was down .6% on a year-over-year basis. During the same period last year, the business earned $2.65 earnings per share. On average, research analysts predict that Becton Dickinson and Co will post 11.7 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.31%. The ex-dividend date of this dividend is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.